September 9, 2020 -- InvestorsHub NewsWire -- via NextBigTicker -- Goldman Small Cap Research updated research on PAO Group, Inc. (USOTC: PAOG) yesterday following PAOG reinstating its “Current Information” status with OTC Markets.  Goldman’s review included a bullish rating and $0.015 PPS 12-month target.  At $0.004, PAOG has a 300% ROI potential.
 


AmericanBULLS is also rates PAOG as bullish (americanbulls.com/PAOG).  “The last pattern detected was bullish with positive implications.”

The PAOG PPS remains well above its 50 day and 200 day moving averages which are both climbing as the PPS bases between $0.003 and $0.004 preparing for its next climb.
 


PAOG recently entered the biotech sector with a proprietary treatment for respiratory disorders derived from a patented cannabis extract.  The treatment is called RespRx.  The company reports having run a trial of its proprietary treatment on COVID-19 patients that has compelled the company to apply for the Coronavirus Treatment Acceleration Program (CTAP).

Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: 
www.nextbigticker.com


Other movers to watch are GAXY, VRUS, and BBRW.

 

SOURCE: NextBigTicker

Verus (CE) (USOTC:VRUS)
過去 株価チャート
から 10 2024 まで 11 2024 Verus (CE)のチャートをもっと見るにはこちらをクリック
Verus (CE) (USOTC:VRUS)
過去 株価チャート
から 11 2023 まで 11 2024 Verus (CE)のチャートをもっと見るにはこちらをクリック